Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

NCT07228663 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT07228663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial
Lead sponsor
McMaster University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
December 1, 2027
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular prevention, hip fracture surgery, venous thromboembolism (vte)